Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR.
Blood. 2020 Aug 20;136(8):989-1001. doi: 10.1182/blood.2020005222.
Matriptase-2 (MT2), encoded by TMPRSS6, is a membrane-anchored serine protease that plays a key role in suppressing hepatic hepcidin expression. MT2 is synthesized as a zymogen and undergoes autocleavage for activation. Previous studies suggest that MT2 suppresses hepcidin by cleaving hemojuvelin and other components of the bone morphogenetic protein-signaling pathway. However, the underlying mechanism is still debatable. Here we dissected the contributions of the nonproteolytic and proteolytic activities of Mt2 by taking advantage of Mt2 mutants and Tmprss6-/- mice. Studies of the protease-dead full-length Mt2 (Mt2S762A) and the truncated Mt2 that lacks the catalytic domain (Mt2mask) indicate that the catalytic domain, but not its proteolytic activity, was required for Mt2 to suppress hepcidin expression. This process was likely accomplished by the binding of Mt2 ectodomain to Hjv and Hfe. We found that Mt2 specifically cleaved the key components of the hepcidin-induction pathway, including Hjv, Alk3, ActRIIA, and Hfe, when overexpressed in hepatoma cells. Nevertheless, studies of a murine iron-refractory iron-deficiency anemia-causing mutant (Mt2I286F) in the complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 domain indicate that Mt2I286F can be activated, but it exhibited a largely compromised ability to suppress hepcidin expression. Coimmunoprecipitation analysis revealed that Mt2I286F, but not Mt2S762A, had reduced interactions with Hjv, ActRIIA, and Hfe. In addition, increased expression of a serine protease inhibitor, the hepatocyte growth factor activator inhibitor-2, in the liver failed to alter hepcidin. Together, these observations support the idea that the substrate interaction with Mt2 plays a determinant role and suggest that the proteolytic activity is not an appropriate target to modulate the function of MT2 for clinical applications.
组织蛋白酶 2(MT2),由 TMPRSS6 编码,是一种膜锚定丝氨酸蛋白酶,在抑制肝脏中血红素蛋白表达方面发挥关键作用。MT2 作为酶原合成,并通过自身切割而激活。先前的研究表明,MT2 通过切割血影蛋白和骨形态发生蛋白信号通路的其他成分来抑制血红素蛋白。然而,其潜在机制仍存在争议。在这里,我们利用 MT2 突变体和 Tmprss6-/- 小鼠来剖析 MT2 的非蛋白水解和蛋白水解活性的贡献。对蛋白酶失活全长 MT2(Mt2S762A)和缺乏催化结构域的截短 MT2(Mt2mask)的研究表明,催化结构域而非其蛋白水解活性对于 MT2 抑制血红素蛋白表达是必需的。这一过程可能是通过 MT2 外显子与 Hjv 和 Hfe 的结合来完成的。我们发现,当在肝癌细胞中过表达时,Mt2 特异性地切割血红素蛋白诱导途径的关键成分,包括 Hjv、Alk3、ActRIIA 和 Hfe。然而,对补体蛋白亚基 C1r/C1s、海胆胚胎生长因子和骨形态发生蛋白 1 结构域中的铁难治性缺铁性贫血致病突变体(Mt2I286F)的研究表明,Mt2I286F 可以被激活,但它抑制血红素蛋白表达的能力大大受损。共免疫沉淀分析显示,Mt2I286F 而不是 Mt2S762A 与 Hjv、ActRIIA 和 Hfe 的相互作用减少。此外,肝脏中肝细胞生长因子激活物抑制剂-2 的表达增加并未改变血红素蛋白。总之,这些观察结果支持这样一种观点,即与 Mt2 的底物相互作用起着决定作用,并表明蛋白水解活性不是调节 MT2 功能的合适靶点,不适合用于临床应用。